Toxicity to chemotherapy treatment in women with breast cancer / Toxicidade ao tratamento quimioterápico em mulheres com câncer de mama

AUTOR(ES)

Thais de Oliveira Gozzo

DATA DE PUBLICAÇÃO

2008

RESUMO

Method: Thais study data were collected retrospectively reviewing the chart of 72 women with breast cancer, underwent to chemotherapy for the first time, that used epirubicin and docetaxel to neoadjuvant treatment and epirubicin and ciclophosphamid to adjuvant treatment. The data collection was done with the charts of women, with 30 to 60 years, treated in 2003 to 2006 in followed in the onco-gynecology and mastology sector- Gynecology and Obstetric Department of the University of São Paulo at Ribeirão Preto Medical School Hospital das Clínicas. Results: The participants had been divided in two groups, one with 31 women who had presented neutropenia and the other with 41 that had not presented. The average of age of the participants was of 47,8 years. The gastrointestinal toxicities during the neoadjuvant and adjuvant treatment observed mucositis (8.4% and 2%), nausea (18.6% and 18%) and vomiting (3.3% and 18%). Another observed toxicity was the extravasation during the chemotherapy treatment that occurred in 17 (23.6%) women. Was observed that 43% of the women had respectively presented neutropenia, who analyzed between the chemotherapy cycles had been statistical significant for cycles two and three of the neoadjuvant with values of p = 0,0016 and 0,0009 respectively, for cycles two and three of the adjuvant with values of p =0.0014 and 0.0030. And for the end of the neoadjuvant treatment, previous treatment to the surgical treatment being p-valor=<0,0001 and for the end of the adjuvant treatment, with p-valor=<0.0004. To anemia occurrence, this was not related with the presence or not of neutropenia, however it was observed that had a fall in the values of HB during the neoadjuvant, with fast recovery in the period of adjuvant. However, did not have recovery to previous the average values to the chemoterapy treatment. The reduction of the dose was used for six women in result of the hematologic toxicity. Was registered 152 doses delays between the chemotherapy cycles. The Log-Rank test for the time of treatment and survival, concluded that was equal for both groups. Conclusion: Through the results of this study demonstrates the necessity of develop and implement protocols for nursing care to women with breast cancer in order to assess the adverse events and most appropriate management of them

ASSUNTO(S)

adverse effects enfermagem efeitos adversos protocolos de quimioterapia combinada antineoplásica antineoplastic combined chemotherapy protocols neoplasias mammary nursing neoplasias mamárias

Documentos Relacionados

• Toxicidade ao tratamento quimioterápico em mulheres com câncer de mama
• Neutropenia e qualidade de vida em mulheres com câncer de mama durante o tratamento quimioterápico
• Characterization of pain in women with breast cancer after treatment.
• AvaliaÃÃo do Tratamento Adjuvante com Tamoxifeno em Mulheres com CÃncer de Mama.
• Trauma vascular: ocorrência em pessoas submetidas a tratamento quimioterápico para câncer de mama